Agomab Therapeutics NVAGMB
13F holders, Q1 2026 (March 31)32holders
3famous investors
$10.50avg. 13F price*
At the end of Q1 2026, 32 institutions reported holding Agomab Therapeutics NV (AGMB) in their 13F filings. The largest holders were EQT Fund Management S.a r.l. ($53.9M), Sanofi ($29.2M) and Cormorant Asset Management, LP ($25.9M). 3 famous investors held it, including Israel Englander (0.0% of Millennium Management's portfolio), Ken Griffin (0.0% of Citadel Advisors's portfolio) and David E. Shaw (0.0% of D. E. Shaw & Co.'s portfolio).
- Company
- Agomab Therapeutics NV
- CUSIP
- 00860C102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 32 | $245.3M |
| Exits | 0 | $0 |
Ownership 32 holders
| EQT Fund Management S.a r.l. | 5.28% | New | 5,141,992 | $53.9M |
| Sanofi | 8.69% | New | 2,783,096 | $29.2M |
| Cormorant Asset Management, LP | 1.30% | New | 2,465,348 | $25.9M |
| TCG Crossover Management, LLC | 0.62% | New | 2,053,233 | $21.5M |
| Federated Hermes, Inc. | 0.03% | New | 1,618,000 | $17.0M |
| Casdin Capital, LLC | 1.23% | New | 1,550,000 | $16.3M |
| Andera Partners | 9.12% | New | 1,538,702 | $16.1M |
| FMR LLC | 0.00% | New | 1,458,677 | $15.3M |
| Nantahala Capital Management, LLC | 0.81% | New | 1,200,000 | $12.9M |
| Aberdeen Group plc | 0.01% | New | 707,656 | $7.4M |
| Samsara Biocapital, LLC | 0.61% | New | 600,000 | $6.3M |
| Perceptive Advisors LLC | 0.12% | New | 600,000 | $6.3M |
| Siren, L.L.C. | 0.12% | New | 411,250 | $4.3M |
| LMR Partners LLP | 0.04% | New | 300,000 | $3.1M |
| Seven Grand Managers, LLC | 0.14% | New | 200,000 | $2.1M |
| Redmile Group, LLC | 0.11% | New | 156,250 | $1.6M |
| Millennium Management | 0.00% | New | 95,233 | $999K |
| Pfizer Inc | 0.34% | New | 75,000 | $814K |
| Alyeska Investment Group, L.P. | 0.00% | New | 75,000 | $787K |
| Laurion Capital Management LP | 0.05% | New | 50,000 | $525K |
| Bellevue Group AG | 0.01% | New | 50,000 | $525K |
| Sectoral Asset Management Inc. | 0.40% | New | 43,500 | $477K |
| Goldman Sachs Group Inc. | 0.00% | New | 35,739 | $375K |
| Burkehill Global Management, LP | 0.02% | New | 35,000 | $367K |
| Citadel Advisors | 0.00% | New | 35,000 | $367K |
| HRT Financial LP | 0.00% | New | 23,726 | $248K |
| D. E. Shaw & Co. | 0.00% | New | 15,326 | $161K |
| Two Sigma Investments, LP | 0.00% | New | 14,241 | $149K |
| Jane Street Group, LLC | 0.00% | New | 12,794 | $134K |
| UBS Group AG | 0.00% | New | 6,437 | $68K |
| Morgan Stanley | 0.00% | New | 3,025 | $32K |
| SBI Securities Co., Ltd. | 0.00% | New | 2 | $21 |
"% of holder's portfolio" is AGMB's weight in each manager's 13F, not the share of Agomab Therapeutics NV the manager owns.